Entry Point Capital, LLC Xenon Pharmaceuticals Inc. Transaction History
Entry Point Capital, LLC
- $188 Million
- Q2 2025
Shares
3 transactions
Others Institutions Holding XENE
# of Institutions
227Shares Held
73.4MCall Options Held
435KPut Options Held
207K-
Avoro Capital Advisors LLC New York, NY5.74MShares$207 Million3.12% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.58MShares$165 Million1.68% of portfolio
-
Wellington Management Group LLP Boston, MA3.79MShares$136 Million0.03% of portfolio
-
Janus Henderson Group PLC London, X03.33MShares$120 Million0.06% of portfolio
-
Capital International Investors Los Angeles, CA3.09MShares$111 Million0.02% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.24B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...